MacroGenics, Inc.

Insmed capitalized on the company’s better-than-expected Phase IIb clinical trial readout for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), which sent its s

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MacroGenics Gets $40m Up Front For St

Incyte Corporation is going to have a second go at getting its PD1 inhibitor Zynyz (retifanlimab) approved as the first anti PD-1/PD-L1 inhibitor for squamous cell anal carcinoma (SCAC) following a h

MacroGenics has seen its share price plummet after Phase II results of its antibody-drug conjugate (ADC) showed a worsening safety profile in metastatic castration-resistant prostate cancer patients,